[go: up one dir, main page]

AR106146A1 - ANTI-TIGIT ANTIBODIES AND METHODS OF USE - Google Patents

ANTI-TIGIT ANTIBODIES AND METHODS OF USE

Info

Publication number
AR106146A1
AR106146A1 ARP160102929A ARP160102929A AR106146A1 AR 106146 A1 AR106146 A1 AR 106146A1 AR P160102929 A ARP160102929 A AR P160102929A AR P160102929 A ARP160102929 A AR P160102929A AR 106146 A1 AR106146 A1 AR 106146A1
Authority
AR
Argentina
Prior art keywords
methods
tigit
tigit antibodies
human tigit
antibody
Prior art date
Application number
ARP160102929A
Other languages
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR106146A1 publication Critical patent/AR106146A1/en

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a anticuerpos anti-TIGIT (inmunorreceptor de células T con dominios de Ig e ITIM) y métodos de uso de los mismos. Reivindicación 1: Un anticuerpo que se une específicamente a TIGIT humano caracterizado porque el anticuerpo se une a un epítope sobre TIGIT humano que comprende uno o más de los residuos de aminoácidos Ser78, Ser80, y Lys82 de TIGIT humano.The present application relates to anti-TIGIT antibodies (T-cell immunoreceptor with Ig and ITIM domains) and methods of use thereof. Claim 1: An antibody that specifically binds to human TIGIT characterized in that the antibody binds to an epitope on human TIGIT comprising one or more of the amino acid residues Ser78, Ser80, and Lys82 of human TIGIT.

ARP160102929A 2015-09-25 2016-09-26 ANTI-TIGIT ANTIBODIES AND METHODS OF USE AR106146A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562233230P 2015-09-25 2015-09-25

Publications (1)

Publication Number Publication Date
AR106146A1 true AR106146A1 (en) 2017-12-13

Family

ID=60931770

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160102929A AR106146A1 (en) 2015-09-25 2016-09-26 ANTI-TIGIT ANTIBODIES AND METHODS OF USE
ARP210100111A AR121189A2 (en) 2015-09-25 2021-01-18 ANTI-TIGIT ANTIBODIES AND METHODS OF USE

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210100111A AR121189A2 (en) 2015-09-25 2021-01-18 ANTI-TIGIT ANTIBODIES AND METHODS OF USE

Country Status (1)

Country Link
AR (2) AR106146A1 (en)

Also Published As

Publication number Publication date
AR121189A2 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
CL2021000716A1 (en) Antibody constructs for flt3 and cd3. (divisional sol. 201800269)
ZA202401297B (en) Anti-tigit antibodies and methods of use
CL2019003095A1 (en) Anti-cd33 antibodies and methods of using them.
CL2018000270A1 (en) Antibody constructs for cd70 and cd3.
CO2018010538A2 (en) Specific poliovirus receptor (rvp) antibodies
CL2019003093A1 (en) Anti-trem2 antibodies and methods of using them.
CL2018000267A1 (en) Bispecific antibody constructs that bind dll3 and cd3
MX2019011927A (en) Anti-ilt4 antibodies and antigen-binding fragments.
MX2018003410A (en) Humanized anti-human cd19 antibodies and methods of use.
MX2024006565A (en) PRO/LATENT ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE THEREOF.
BR112021004316A2 (en) Anti-Tren-2 Agonist Antibodies
CL2018000378A1 (en) Receptors of chimeric antigens based on single domain antibodies and methods of use of these
CL2018000263A1 (en) Bispecific antibody constructs that bind to egfrviii and cd3.
ECSP17083779A (en) IMMUNORECEPTOR BINDING AGENTS OF T-CELLS WITH GI DOMAINS AND INHIBITION MOTIVES BASED ON IMMUNORECEPTOR TYROSINE (TIGIT) AND USES THEREOF
MX2017012802A (en) ANTISORTILINE ANTIBODIES AND METHODS FOR USE.
UY36245A (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
CR20160338A (en) ANTIBODIES AND METHODS OF USE
MX2020002395A (en) METHODS TO EVALUATE ANTIBODIES AND DRUG CONJUGATES.
MX2015009819A (en) SPECIFIC HUMAN ANTIBODY TO HUMAN METAPNEUMOVIRUS, OR FRAGMENT OF UNION TO THE ANTIGEN OF THE SAME.
AR106146A1 (en) ANTI-TIGIT ANTIBODIES AND METHODS OF USE
AR113854A1 (en) ANTI-CXCR5 ANTIBODIES, COMPOSITIONS AND USES THEREOF
AR133026A2 (en) Antibody constructs for DLL3 and CD3
AR115312A1 (en) C-TERMINAL ANTIBODY VARIANTS
AR105316A1 (en) ANTIBODIES AGAINST THE TRANSFERRINE RECEIVER (ANTI-CD71), ANTI-CD71 ACTIVABLES ANTIBODIES AND THEIR METHODS OF USE